
21st Century Cures Brings Hope for Rare Disease Research
However, not everyone supports the bill's provisions that promote the development of pediatric rare disease drugs through the "voucher" incentive.
The 21st Century Cures bill, which was
Approximately 15 million children are diagnosed with rare diseases, which can result in nearly 35% of deaths in the first year of life.
Pharmaceutical companies are often cautious about venturing into the world of rare diseases for several reasons: fear of potential negative outcomes, limited returns, increased stringency with clinical trials in children, etc. Therefore, to motivate the pharmaceutical industry to invest efforts in developing theses drugs, the Congress initiated a voucher program in 2011 which allows the company to have another one of their drugs approved quicker than usual. The company can also sell this voucher if they so desire.
The Cures bill is seeking an extension on this voucher program, which is scheduled to expire next year.
However, not everyone is happy with this program. Read more at Kaiser Health News:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.